BTG brushes off antivenin sales glitch
This article was originally published in Scrip
BTG says a drop in first-half sales of the snake bite antidote that it acquired with Protherics in December 2008 was a one-off "timing issue", related to technical problems at a third-party supplier. It said that the end-user market had suffered no shortage because its partner Nycomed had sufficient inventory. The problems have now been resolved with a recovery plan in place meaning that the shortfalls should be made up in the second half of the UK speciality pharmaceutical company's financial year.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.